Christopher Philbey
Impact in
- Infectious Diseases top 2%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
-
- Antibiotic Use and Resistance
Papers in
-
- COVID-19 Clinical Research Studies 3
-
- Diabetes Management and Research 2
- Partner nations
- United KingdomVietnamNepal
In The Last Decade
Christopher Philbey
5 papers receiving 920 citations
Christopher Philbey's Hit Papers
Peers
Comparison fields: 5 of 69
- Infectious Diseases 706
- Applied Microbiology and Biotechnology 34
- Internal Medicine 27
- Endocrinology, Diabetes and Metabolism 59
- Obstetrics and Gynecology 20
Countries citing papers authored by Christopher Philbey
This map shows the geographic impact of Christopher Philbey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Philbey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Philbey more than expected).
Fields of papers citing papers by Christopher Philbey
This network shows the impact of papers produced by Christopher Philbey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Philbey. The network helps show where Christopher Philbey may publish in the future.
No co-authors to show.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2021 | 411 |
| 2 | Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2022 | 282 |
| 3 | 2021 | 213 | |
| 4 | 2023 | 59 | |
| 5 | 2025 | 2 |
About Christopher Philbey
Christopher Philbey is a scholar working on Infectious Diseases, Endocrinology, Diabetes and Metabolism, Nuclear Energy and Engineering, Waste Management and Disposal and Organic Chemistry, having authored 5 papers that have together received 967 indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (3 papers) and Diabetes Management and Research (2 papers). The work is most often cited by research in Infectious Diseases (706 citations), Applied Microbiology and Biotechnology (34 citations), Internal Medicine (27 citations), Endocrinology, Diabetes and Metabolism (59 citations) and Obstetrics and Gynecology (20 citations). Christopher Philbey has collaborated with scholars based in United Kingdom, Vietnam and Nepal. Their work appears in journals such as The Lancet, Diabetes Care and Diabetes Technology & Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.